北陆药业：钆布醇注射剂拟中选第十一批全国药品集中采购

Core Viewpoint - Beilu Pharmaceutical (300016.SZ) announced that its Gadobutrol injection has been selected for the 11th batch of national centralized drug procurement, which is expected to enhance the company's market share and brand influence in the contrast agent segment [1] Group 1: Product Approval and Sales Performance - The Gadobutrol injection received its drug registration certificate in April 2022 and the supplementary application approval in April 2024 [1] - The sales amount for the product in 2024 is 4.6859 million yuan, accounting for 0.48% of the company's total revenue for that year [1] - For the first three quarters of 2025, the sales amount reached 5.7854 million yuan, representing 0.67% of the company's revenue during that period [1] Group 2: Market Opportunities and Uncertainties - The execution of the procurement results is expected to rapidly open up the market for the Gadobutrol injection [1] - There are uncertainties regarding the signing of procurement contracts and the market sales execution following the centralized procurement [1] - The company will closely monitor the developments and disclose information in a timely manner [1]